A proprietary novel delivery technology that provides short-acting mucosal topical pain relief during placement of an intrauterine device (IUD).  The product has additional potential applicability to other important medical procedures including certain types of hysteroscopies.

Lidbree will be submitted for European regulatory review in 2018 and will be further developed for future market introduction in the US. Lidbree is not available for commercial sale in the U.S.